HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for generic versions of Xanax® XR, (Alprazolam) 0.5 mg, 1 mg, 2 mg and 3 mg Extended-release Tablets. Pharmacia and Upjohn markets Xanax XR for the management of anxiety disorder or the short-term relief of symptoms of anxiety. IMPAX’ Global Pharmaceuticals division plans to launch the product soon.
